The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-290-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.14 million
Profitability
Miscellaneous
Employees62
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
The Medicines (NASDAQ:MDCO) Frequently Asked Questions
What is The Medicines' stock symbol?
The Medicines trades on the NASDAQ under the ticker symbol "MDCO."
How were The Medicines' earnings last quarter?
The Medicines Company (NASDAQ:MDCO) released its quarterly earnings data on Wednesday, July, 24th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. During the same period last year, the firm posted ($0.63) EPS. View The Medicines' Earnings History.
When is The Medicines' next earnings date?
What price target have analysts set for MDCO?
14 Wall Street analysts have issued 12-month price objectives for The Medicines' stock. Their forecasts range from $48.00 to $145.00. On average, they expect The Medicines' share price to reach $73.33 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price. View Analyst Price Targets for The Medicines.
What is the consensus analysts' recommendation for The Medicines?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.
Has The Medicines been receiving favorable news coverage?
News coverage about MDCO stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. The Medicines earned a news impact score of -3.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the next several days. View News Stories for The Medicines.
Are investors shorting The Medicines?
The Medicines saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 24,350,000 shares, an increase of 5.6% from the August 30th total of 23,050,000 shares. Based on an average trading volume of 2,080,000 shares, the days-to-cover ratio is presently 11.7 days. Approximately 32.2% of the shares of the company are sold short. View The Medicines' Current Options Chain.
Who are some of The Medicines' key competitors?
Some companies that are related to The Medicines include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of The Medicines own?
Who are The Medicines' key executives?
The Medicines' management team includes the folowing people:
- Mr. Mark Timney, CEO & Director (Age 54)
- Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
- Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
- Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
- Dr. Goutham Krishna Gorti, VP & Head of Investor Relations
Who are The Medicines' major shareholders?
The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.19%), Bailard Inc. (0.08%), CIBC Private Wealth Group LLC (0.07%), State of Alaska Department of Revenue (0.07%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.02%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.
Which major investors are selling The Medicines stock?
Which major investors are buying The Medicines stock?
MDCO stock was bought by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Strs Ohio, Envestnet Asset Management Inc., Meeder Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC and Nisa Investment Advisors LLC. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.
How do I buy shares of The Medicines?
Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is The Medicines' stock price today?
One share of MDCO stock can currently be purchased for approximately $57.57.
How big of a company is The Medicines?
The Medicines has a market capitalization of $4.57 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.
What is The Medicines' official website?
How can I contact The Medicines?
The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]
MarketBeat Community Rating for The Medicines (NASDAQ MDCO)
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
